## Jianyang Wang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2042541/publications.pdf Version: 2024-02-01



LIANVANC WANC

#	Article	IF	CITATIONS
1	MiRâ€320b/RAD21 axis affects hepatocellular carcinoma radiosensitivity to ionizing radiation treatment through DNA damage repair signaling. Cancer Science, 2021, 112, 575-588.	3.9	31
2	Role of radiotherapy in treating patients with primary malignant mediastinal nonâ€seminomatous germ cell tumor: A 21â€year experience at a single institution. Thoracic Cancer, 2015, 6, 399-406.	1.9	21
3	Comparison of Treatment Outcomes With Breast-conserving Surgery Plus Radiotherapy Versus Mastectomy for Patients With Stage I Breast Cancer: A Propensity Score-matched Analysis. Clinical Breast Cancer, 2018, 18, e975-e984.	2.4	21
4	Clinical outcomes and radiation pneumonitis after concurrent <scp>EGFR</scp> â€ŧyrosine kinase inhibitors and radiotherapy for unresectable stage <scp>III</scp> nonâ€small cell lung cancer. Thoracic Cancer, 2021, 12, 814-823.	1.9	17
5	The clinical utility of dynamic ctDNA monitoring in inoperable localized NSCLC patients. Molecular Cancer, 2022, 21, 117.	19.2	15
6	Efficacy of dacomitinib in patients with <scp>EGFR</scp> â€mutated <scp>NSCLC</scp> and brain metastases. Thoracic Cancer, 2021, 12, 3407-3415.	1.9	14
7	Epithelial circulating tumor cells with a heterogeneous phenotype are associated with metastasis in NSCLC. Journal of Cancer Research and Clinical Oncology, 2022, 148, 1137-1146.	2.5	12
8	Evaluation of Privacy Risks of Patients' Data in China: Case Study. JMIR Medical Informatics, 2020, 8, e13046.	2.6	10
9	S-1–Based Chemoradiotherapy Followed by Consolidation Chemotherapy With S-1 in Elderly Patients With Esophageal Squamous Cell Carcinoma: A Multicenter Phase II Trial. Frontiers in Oncology, 2020, 10, 1499.	2.8	9
10	Development and external validation of a nomogram to predict four or more positive nodes in breast cancer patients with one to three positive sentinel lymph nodes. Breast, 2020, 53, 143-151.	2.2	9
11	Endostar ( <scp>rhâ€endostatin</scp> ) improves efficacy of concurrent chemoradiotherapy for locally advanced <scp>nonâ€small</scp> cell lung cancer: A systematic review and <scp>metaâ€analysis</scp> . Thoracic Cancer, 2021, 12, 3208-3215.	1.9	9
12	Postoperative intensity-modulated radiation therapy provides favorable local control and low toxicities in patients with soft tissue sarcomas in the extremities and trunk wall. OncoTargets and Therapy, 2015, 8, 2843.	2.0	8
13	Tumor Mutation Load: A Novel Independent Prognostic Factor in Stage IIIA-N2 Non-Small-Cell Lung Cancer. Disease Markers, 2019, 2019, 1-10.	1.3	7
14	A multicenter prospective phase III clinical randomized study of simultaneous integrated boost intensity-modulated radiotherapy with or without concurrent chemotherapy in patients with esophageal cancer: 3JECROG P-02 study protocol. BMC Cancer, 2020, 20, 901.	2.6	7
15	Efficacy and safety of immune checkpoint inhibitor consolidation after chemoradiation in patients of Asian ethnicity with unresectable stage <scp>III</scp> nonâ€small cell lung cancer: Chinese multicenter report and literature review. Thoracic Cancer, 2020, 11, 2916-2923.	1.9	7
16	A validation study on the lung immune prognostic index for prognostic value in patients with locally advanced non–small cell lung cancer. Radiotherapy and Oncology, 2021, 156, 244-250.	0.6	7
17	Risk of cardiacâ€related mortality in stage <scp>IIIAâ€N2</scp> nonâ€small cell lung cancer: Analysis of the Surveillance, Epidemiology, and End Results (SEER) database. Thoracic Cancer, 2021, 12, 1358-1365.	1.9	6
18	Additional Radiotherapy With or Without Chemotherapy Following Endoscopic Resection for Stage I Esophageal Carcinoma: A Pilot Study. Technology in Cancer Research and Treatment, 2021, 20, 153303382110480.	1.9	5

JIANYANG WANG

#	Article	IF	CITATIONS
19	Locoregional recurrence patterns in women with breast cancer who have not undergone post-mastectomy radiotherapy. Radiation Oncology, 2020, 15, 212.	2.7	4
20	A Nomogram for Predicting Brain Metastasis in IIIA-N2 Non-Small Cell Lung Cancer After Complete Resection: A Competing Risk Analysis. Frontiers in Oncology, 2021, 11, 781340.	2.8	4
21	Chemoradiotherapy is an alternative choice for patients with primary mediastinal seminoma. Radiation Oncology, 2022, 17, 58.	2.7	4
22	Development and validation of a prediction model using molecular marker for longâ€ŧerm survival in unresectable stage <scp>III</scp> nonâ€small cell lung cancer treated with chemoradiotherapy. Thoracic Cancer, 2022, 13, 296-307.	1.9	4
23	High-sensitive C-reactive protein predicts outcome after coronary artery bypass. Asian Cardiovascular and Thoracic Annals, 2012, 20, 525-533.	0.5	3
24	Malignant thrombosis of the superior vena cava caused by non-small-cell lung cancer treated with radiation and erlotinib: a case with complete and prolonged response over 3 years. OncoTargets and Therapy, 2013, 6, 749.	2.0	2
25	Local Therapy Combined With First-Line EGFR Tyrosine Kinase Inhibitor Achieves Favorable Survival in Patients With EGFR-Mutant Metastatic Non-Small Cell Lung Cancer. Clinical Medicine Insights: Oncology, 2022, 16, 117955492210803.	1.3	2
26	Progression-Free Survival and Time to Progression as Potential Surrogate Endpoints for Overall Survival in Chemoradiotherapy Trials in Limited-Stage Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. Frontiers in Oncology, 2022, 12, 810580.	2.8	0